Trial Profile
Single Ascending Dose and Repeat Dose Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, by Intravenous Infusion, or by Inhalation in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs Sargramostim (Primary) ; Sargramostim (Primary) ; Sargramostim (Primary)
- Indications Acute hypoxia; Acute radiation syndrome; Alzheimer's disease; Bone marrow disorders; Chronic lymphocytic leukaemia; COVID 2019 infections; Down syndrome; Haematological malignancies; Malignant melanoma; Neutropenia; Pneumococcal infections; Prostate cancer; Pulmonary alveolar proteinosis; Sepsis; Skin cancer; Stem cell mobilisation
- Focus Pharmacokinetics
- Sponsors Partner Therapeutics
- 30 Sep 2022 Status changed from recruiting to completed.
- 15 May 2022 New trial record